Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population
复制标题
DOI：
10.4088/jcp.v65n1114
复制
发表时间：
2004-11-01
影响因子：
5.3
通讯作者：
Yamawaki, S
中科院分区：
文献类型：
--
作者：
Yamashita, H;Mori, K;Yamawaki, S
目的：目的探讨非典型抗精神病药物利培酮、奥氮平、喹替利嗪和哌罗匹隆对精神分裂症患者主观睡眠质量的影响。方法：92例住院患者（平均年龄59.9岁）均接受常规抗精神病药物治疗，符合精神分裂症DSM-IV诊断标准。受试者被随机分配接受4种非典型抗精神病药物（奥氮平、哌罗匹隆、奎替鲁和利培酮）中的1种。主观睡眠质量和精神病理学评估两次：在基线和转换后8周。数据收集时间为2001年6月至2001年12月。主观睡眠质量评估匹兹堡睡眠质量指数（PSQI），精神病理学的阳性和阴性症状量表（PANSS）。结果：主观睡眠质量评估PSQI与奥氮平，利培酮，或喹替利嗪管理显着改善，但不与哌罗匹隆，与传统的抗精神病药物相比。多元回归分析显示，非典型抗精神病药物治疗后睡眠质量的改善与基线时睡眠质量差有关。此外，睡眠质量的改善与阴性症状的改善显着相关的PANSS.Conclusion：这些结果表明，非典型抗精神病药物改善精神分裂症患者的主观睡眠质量与常规抗精神病药物相比，这表明显着的效力，5-羟色胺-2受体阻滞剂的非典型抗精神病药物可能参与这种改善的机制。这些改善与阴性症状的改善相关。
Objective: To investigate the effects of the atypical antipsychotic drugs risperidone, olanzapine, quetiapine, and perospirone on the subjective quality of sleep in patients with schizophrenia.Method: Subjects were 92 inpatients (mean age = 59.9 years) who had been receiving treatment with conventional antipsychotic drugs and who met the DSM-IV criteria for schizophrenia. Subjects were randomly assigned to receive 1 of 4 atypical antipsychotic drugs (olanzapine, perospirone, quetiapine, and risperidone). Subjective sleep quality and psychopathology were assessed twice: at baseline and 8 weeks after switching. Data were collected from June 2001 to December 2001. Subjective sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI), and psychopathology was measured by the Positive and Negative Syndrome Scale (PANSS).Results: Subjective sleep quality as assessed by the PSQI was significantly improved with administration of olanzapine, risperidone, or quetiapine, but not with perospirone, in comparison with conventional antipsychotic drugs. Multiple regression analysis revealed that the improvement of sleep quality with administration of atypical antipsychotic drugs was predicted by poor sleep quality at baseline. In addition, improvement of sleep quality was significantly correlated with improvement of negative symptoms as assessed by the PANSS.Conclusion: These results demonstrated that atypical antipsychotic drugs improved subjective quality of sleep in patients with schizophrenia compared with conventional antipsychotic drugs, suggesting that the marked potency of serotonin-2 receptor blockade in atypical antipsychotic drugs may be involved in the mechanism of this improvement. These improvements were correlated with improvement of negative symptoms.